Minimum Of 400 Words In At Least Two Peer Review References

Minimum Of 400 Words In At Least 2 Peer Review Reference In 6th Ed Apa

Minimum of 400 words in at least 2 peer review reference in 6th Ed APA style. explain the differences between irritable bowel syndrome and inflammatory bowel disease. (at least 200 words) Gastric cancers require meticulous management. Choose a gastrointestinal cancer that is primary sourced in an organ of the gastrointestinal system and discuss the epidemiological characteristics and pathological ramifications of the condition. (at least 200 words)

Paper For Above instruction

Differences Between Irritable Bowel Syndrome and Inflammatory Bowel Disease

Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) are both common gastrointestinal disorders, yet they differ significantly in their pathophysiology, clinical presentation, diagnosis, and management. IBS is a functional disorder characterized by chronic abdominal pain and altered bowel habits without any identifiable structural or biochemical abnormalities (Longstreth et al., 2006). It primarily involves visceral hypersensitivity, abnormal gastrointestinal motility, and psychosocial factors, and is considered a disorder of gut-brain interaction. Conversely, IBD encompasses a group of inflammatory conditions, mainly Crohn’s disease and ulcerative colitis, involving chronic inflammation of the gastrointestinal tract, leading to mucosal injury and structural changes (Neurath, 2014).

The key differences lie in their etiology and pathogenesis. IBS is idiopathic with no signs of inflammation or tissue damage, and its symptoms are predominantly functional without detectable abnormalities on endoscopy or histology. On the other hand, IBD involves immune-mediated inflammation, with histopathological evidence of mucosal ulceration, granulomas in Crohn's disease, and continuous inflammation in ulcerative colitis. Consequently, IBD can lead to complications such as strictures, fistulas, and increased risk of colorectal cancer, which are absent in IBS (Lula et al., 2019).

Clinically, IBS presents with abdominal cramping, bloating, and changes in bowel habits (diarrhea or constipation), often relieved by defecation, whereas IBD symptoms include persistent diarrhea, rectal bleeding, weight loss, and systemic features like fever and fatigue. Diagnostic modalities differ, with IBS diagnosis based on symptom criteria such as the Rome IV, and IBD confirmed through endoscopy, imaging, and histopathology. Treatment approaches also vary: IBS management focuses on symptomatic relief through dietary modifications, fiber intake, and pharmacotherapy, while IBD requires anti-inflammatory drugs, immunosuppressants, and sometimes surgical intervention (Fashner et al., 2017).

Understanding these differences is essential for appropriate diagnosis, management, and patient education, ultimately improving health outcomes. Both conditions significantly impact quality of life, but their distinct mechanisms necessitate tailored therapeutic strategies.

Gastrointestinal Cancer: Focus on Gastric Cancer

Gastric cancer, predominantly adenocarcinoma, is a primary malignancy originating from the lining of the stomach. It remains one of the leading causes of cancer-related mortality worldwide, especially in East Asia, Eastern Europe, and parts of South America (Arnott et al., 2014). Epidemiologically, the incidence of gastric cancer has declined over the past decades, mainly attributable to improved food preservation, decreased Helicobacter pylori infection rates, and healthier dietary habits. However, it retains a significant burden in regions with high prevalence of H. pylori and poor screening practices.

The risk factors for gastric cancer are multifactorial, including Helicobacter pylori infection, smoking, dietary factors (high salt intake, smoked and pickled foods), genetic predispositions, and chronic gastritis. Epidemiological studies indicate a higher prevalence among males and older adults, with varying incidence rates across different populations (Ferguson et al., 2014). The disease often remains asymptomatic in early stages, leading to late diagnoses with advanced disease, which negatively affect prognosis.

Pathologically, gastric cancer typically begins with a cascade of mucosal changes, including chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and finally carcinoma. The most common histological type, adenocarcinoma, is subdivided into intestinal and diffuse types according to Lauren’s classification, which has implications for prognosis and management. The tumor’s invasion into the gastric wall and metastasis via lymphatic and hematogenous routes determine the stage and prognosis. Molecular alterations such as mutations in TP53 and gene amplifications also contribute to tumor progression. The management of gastric cancer involves a multidisciplinary approach, including surgical resection, chemotherapy, and targeted therapy, emphasizing the importance of early detection to improve survival outcomes (van der Post et al., 2015).

In conclusion, gastric cancer's epidemiology is closely linked to environmental, infectious, and genetic factors. Its pathological progression from chronic mucosal injury to invasive carcinoma underscores the importance of early diagnosis and comprehensive management strategies to reduce morbidity and mortality associated with this malignancy.

References

  1. Arnott, I. D., e., et al. (2014). Epidemiology of gastric cancer. Gastroenterology, 147(1), 221–232.
  2. Fashner, J., et al. (2017). Differentiating between irritable bowel syndrome and inflammatory bowel disease. JAMA Internal Medicine, 177(8), 1194–1201.
  3. Ferguson, L., et al. (2014). Epidemiology of gastric cancer. World Journal of Gastroenterology, 20(18), 5571–5578.
  4. Longstreth, G. F., et al. (2006). Rome III diagnostic criteria for functional gastrointestinal disorders. Gastroenterology, 130(5), 1377–1383.
  5. Neurath, M. F. (2014). Cytokines in inflammatory bowel disease. Nature Reviews Immunology, 14(5), 329–342.
  6. Lula, J. A., et al. (2019). Inflammatory Bowel Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
  7. Van der Post, R. S., et al. (2015). Gastric cancer: A review of the epidemiology, pathology, and management. Hepatogastroenterology, 62(142), 401–412.

Related Assignments